| Autor: |
Hua Jiang |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Urology Case Reports, Vol 57, Iss , Pp 102742- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2214-4420 |
| DOI: |
10.1016/j.eucr.2024.102742 |
| Popis: |
Abstrcat: Basal cell carcinoma (BCC) of the prostate is a rare and enigmatic tumor with uncertain biological behavior and treatment modalities. Some studies suggest that BCC exhibits invasive characteristics and a high degree of malignancy, necessitating proactive management and vigilant monitoring. Notably, there is a lack of reported effective treatment utilizing programmed cell death protein-1 (PD-1) inhibitors for advanced BCC of the prostate. This study explores the efficacy of tislelizumab, as a single-agent therapy, in the successful treatment of advanced prostate BCC. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
